th– Live video webcast on Tuesday, February 10 at 1:20 PM EST â"¢ Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital fr ...

SAN RAMON, Calif.--(BUSINESS WIRE)--Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) ("Grid Dynamics†), a leader in enterprise-level digital transformation services and solutions, today announced that it will host a video conference call at 4:30 p.m. ET on Thursday, March 5, 2026 to discuss its fourth quarter and full year 2025 financial results. A press release containing these results will be available on our website prior to the call. A webcast of the video conference call, as well as a replay av. ...

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.Cadre Holdings (NYSE: CDRE ), a provider of protective gear and equipment for law enforcement and nuclear markets, has gained 30% since my last report sharply outperforming the S&P 500’s 6.2% gain. In my priorDhierin-Perkash Bechai is an aerospace, ...

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)---- $VENU #Appraisal--Venu Holding Corporation ("VENU" or the "Company") (NYSE American: VENU), owner, operator, and developer of premium entertainment and hospitality destinations, has completed a comprehensive nationwide review of its real estate portfolio, resulting in a third-party appraised value of $1.24 billion. "As we continue to build VENU, we remain focused on creating a company with a strong and transparent asset foundation,†said J.W. Roth, Founder, Chairm ...

You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters. Steward Partners, an employee-owned hybrid partnership of independent advisory firms with nearly $50 billion in client assets, has added a team of advisors from Raymond James & Associates, the firm’s employee broker/dealer channel. Steward said in a LinkedIn post that the Silcox & Avonda Wealth Management team, based in Stuart, Fla., has joined the firm.  The team, led by Peter Silcox and ...

Key Takeaways ALGN posted Q4 adjusted EPS of $3.29 and $1.05B revenues, beating estimates and lifting shares 13% higher.ALGN's Clear Aligner revenues rose 5.5% on 676.9k cases, while Systems & Services grew 4.2%.ALGN saw gross margin fall 477 bps and operating margin drop to 15.2% as costs of net revenues jumped.Align Technology, Inc. (ALGN) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of $3.29, up 34.8% from the year-ago level. The bottom line surpassed the Zacks Consensus Estimate by 10 ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.33%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.48 per share when it actually produced earnings of $1.63, delivering a surprise of +10.14%.Over the last four ...

WEC Energy Group (WEC) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.75%. A quarter ago, it was expected that this electricity and natural gas provider would post earnings of $0.79 per share when it actually produced earnings of $0.83, delivering a surprise of +5.06%.Over the las ...

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.65%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.39 per share when it actually produced a loss of $0.37, delivering a surprise of +5.13%.Over the last four quarters, the ...

Hershey forecast annual sales and profit above Wall Street estimates on Thursday, supported by resilient demand for its confectionery and salty snacks and continued benefits of earlier price hikes imp... ...